1yr
.png?VersionId=X.GIuwYa4CH.pBk4mXaQzfvoNQjySO44)
1yr
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37870973/
Treatment with selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab among patients with advanced RET fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov...
Selpercatinib showed significantly longer progression-free survival and higher response rates than platinum-based chemotherapy (with/without pembrolizumab) in RET fusion-positive NSCLC, with CNS efficacy and consistent adverse events (NCT04194944).
1yr
The Evolving Treatment Landscape of Medullary Thyroid Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37979019/
Genetic assessment is crucial to address the correct treatment for advanced medullary thyroid cancer (MTC). Multi tyrosine kinase inhibitors (mTKIs) cabozantinib and vandetanib are good first line options, even vandetanib...
For advanced medullary thyroid cancer (MTC), genetic assessment guides treatment: cabozantinib/vandetanib for first-line, pralsetinib for RET mutations, selpercatinib post-mTKIs, and clinical trials or alternative mTKIs thereafter.
1yr
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38255638/
Patients with differentiated thyroid cancer usually present with early-stage disease and undergo surgery followed by adjuvant radioactive iodine ablation, resulting in excellent clinical outcomes and prognosis. However, a minority of...
Differentiated thyroid cancer patients often have good outcomes, but some develop radioactive iodine refractory disease. Tyrosine kinase inhibitors like Lenvatinib and Cabozantinib offer new treatment options for these patients.
1yr
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38828957/
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...
Selpercatinib significantly reduces CNS progression and delays new metastases in RET fusion-positive NSCLC, demonstrating efficacy in treating existing CNS disease and emphasizing the need for RET fusion identification.